Interestingly, due to the characteristic defects in DNA repair seen in BRCA1 mutation-associated tumours, sensitivities to standard cytotoxic agents differ compared with other breast cancers (Bhattacharyya et al, 2000; Quinn et al, 2003). This evidence concerns the gene BRCA1 and neoplasm.